Randomized, double-blind comparison of two nelfinavir doses plus nucleosides in HIV-infected patients (Agouron study 511)

AIDS

Volumn 15, Issue 15, 2001, Pages 1971-1978

  Saag, Michael S ^a   Tebas, Pablo ^b   Sension, Michael ^c   Conant, Marcus ^d   Myers, Robert ^e   Chapman, Sharon K ^f   Anderson, Robert ^f  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Broward General Hospital   (United States)

^d Conant Medical Group ^*  (United States)

^e Phoenix Body Positive   (United States)

^f AGOURON PHARMACEUTICALS INC   (United States)

Author keywords

Antiretroviral combination therapy; Antiretroviral naive; Lamivudine; Onelfinavir; Pivotal study; Plasma HIV RNA; Zidovudine

Indexed keywords

CD4 ANTIGEN; LAMIVUDINE; NELFINAVIR; PLACEBO; VIRUS RNA; ZIDOVUDINE;

ADOLESCENT; ADULT; ANTIVIRAL ACTIVITY; ARTICLE; ASTHENIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLATULENCE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MALE; NELFINAVIR; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TREATMENT OUTCOME; ZIDOVUDINE;

EID: 0035914035     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200110190-00009     Document Type: Article

References (30)

1. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease
2. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
3. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
4. A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy
5. Comparative studies of two-times-daily versus three-times-daily indinavir in combination with zidovudine and lamivudine
6. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1
7. Combination nucleoside analogs plus nelfinavir, nevirapine, or ritonavir in stable antiretroviral therapy-experienced HIV-infected children
8. Radomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients
9. Cerebrospinal fluid HIV-1 RNA during treatment with ritonavir/saquinavir or ritonavir/saquinavir/stavudine
10. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine
11. Reductions in viral load and increases in T lymphocyte numbers in treatment-naive patients with advanced HIV-1 infection treated with ritonavir, zidovudine and zalcitabine triple therapy
12. Decay characteristics of HIV-1-infected compartments during combination therapy
13. 3-Year suppression of HIV viremia with indinavir, zidovudine, and lamivudine
14. Rational design of peptide-based HIV proteinase inhibitors
15. Preclinical pharmacokinetics and distribution to tissue of AG1343, an inhibitor of human immunodeficiency virus type 1 protease
16. Safety, pharmacokinetics, and antiretroviral activity of the potent, specific human immunodeficiency virus protease inhibitor nelfinavir: Results of a phase I/II trial and extended follow-up in patients infected with human immunodeficiency virus
17. A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection
18. Analyzing laboratory marker changes in AIDS clinical trials
19. Comparing treatment groups on the basic of slopes, area-under-the curve, and other summary measures
20. Saquinavir soft gel capsule (SGC) in combination with AZT and 3TC in treatment naive patients
21. Fortovase (saquinavir soft gel capsule; SQV-SGC) in combination with AZT and 3TC in antiretroviral-naive HIV-1 infected patients
22. Saquinavir soft gel capsule (SGC) in combination with AZT and 3TC in treatment naive patients
23. A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients
24. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial
25. A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: The Spanish Earth-1 study
26. Suppression of plasma virus load below the detection limit of a human immunodeficiency virus kit is associated with longer virologic response than suppression below the limit of quantitation
27. A randomized phase II dose range-finding study of the HIV protease inhibitor VIRACEPT® as monotherapy in HIV positive patients
28. A phase II dose escalation study of the agouron protease inhibitor AG 1343
29. The treatment (TX) of nelfinavir (NFV) induced diarrhea (NFVID)